The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, ...

Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...